Literature DB >> 12052408

Eales disease--an update.

Jyotirmay Biswas1, Tarun Sharma, Lingam Gopal, Hajib N Madhavan, K N Sulochana, S Ramakrishnan.   

Abstract

Eales disease, first described by Henry Eales in 1880, remains an enigma. The disease, observed more commonly in the Indian subcontinent than in the rest of the world, occurs in young healthy adult males, initially presenting as retinal periphlebitis and later as retinal ischemia that may lead to vascular alterations and neovascularization. Recurrent vitreous hemorrhage with or without retinal detachment is the common sequelae. In recent years, immunological, molecular biological, and biochemical studies have indicated the role of human leukocyte antigen, retinal autoimmunity, mycobacterium tuberculosis genome, and free radical mediated damage in the etiopathogenesis of this disease. However, its etiology appears to be multifactorial. The management depends on the stage of the disease and consists of medical treatment with oral corticosteroids in the active inflammatory stage and laser photocoagulation in the advanced retinal ischemia and neovascularization stages. The results of vitreoretinal surgery have been found to be satisfactory in case of vitreous hemorrhage with or without retinal detachment.

Entities:  

Mesh:

Year:  2002        PMID: 12052408     DOI: 10.1016/s0039-6257(02)00288-6

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  19 in total

1.  Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease.

Authors:  Atul Kumar; Sri Vatsa Sehra; M B Thirumalesh; Varun Gogia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-15       Impact factor: 3.117

2.  Diagnostic pitfalls: a case of neurosarcoidosis mimicking tuberculous meningitis.

Authors:  Franziska Scheibe; Holger Flick; Oliver Wengert; Daniel Wittschieber; Georg Bohner; Peter Ruokonen; Lutz Harms; Klemens Ruprecht; Klemens Angstwurm
Journal:  J Neurol       Date:  2012-02-04       Impact factor: 4.849

3.  A 44-year-old man with eye, kidney, and brain dysfunction.

Authors:  Ivana Vodopivec; Derek H Oakley; Cory A Perugino; Nagagopal Venna; E Tessa Hedley-Whyte; John H Stone
Journal:  Ann Neurol       Date:  2016-03-07       Impact factor: 10.422

4.  Risk of Retinal Neovascularization in Cases of Uveitis.

Authors:  Apurva K Patel; Craig W Newcomb; Teresa L Liesegang; Siddharth S Pujari; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; H Nida Sen; Pichaporn Artornsombudh; Srishti Kothari; John H Kempen
Journal:  Ophthalmology       Date:  2015-12-11       Impact factor: 12.079

5.  Profiling of human leukocyte antigens in Eales disease and tuberculosis.

Authors:  Shan-jun Cai; Gang Su; Hong Li; Bing Xie; Jun-min Luo
Journal:  Int Ophthalmol       Date:  2013-02-06       Impact factor: 2.031

6.  Differential diagnosis of retinal vasculitis.

Authors:  Ahmed M Abu El-Asrar; Carl P Herbort; Khalid F Tabbara
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

7.  Tubercular retinal vasculitis.

Authors:  Maria Sara Patricio; Joana Portelinha; Maria Picoto Passarinho; Marta Esteves Guedes
Journal:  BMJ Case Rep       Date:  2013-06-03

Review 8.  A clinical approach to the diagnosis of retinal vasculitis.

Authors:  Ahmed M Abu El-Asrar; Carl P Herbort; Khalid F Tabbara
Journal:  Int Ophthalmol       Date:  2009-02-04       Impact factor: 2.031

9.  Treatment of neuro-ophthalmologic manifestations of tuberculosis.

Authors:  Susannah Mistr; Pamela S Chavis
Journal:  Curr Treat Options Neurol       Date:  2006-01       Impact factor: 3.972

10.  Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease.

Authors:  Narayanasamy Angayarkanni; Radhakrishnan Selvi; Rishi Pukhraj; Jyotirmoy Biswas; Shah J Bhavesh; Joyce Tombran-Tink
Journal:  J Ocul Biol Dis Infor       Date:  2009-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.